Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques
Viox E, Richard J, Grandea A, Nguyen K, Harper J, Auger J, Ding S, Gasser R, Prévost J, Marchitto L, Medjahed H, Bourassa C, Gaudette F, Pagliuzza A, Trifone C, Gavegnano C, Hurwitz S, Park J, Clark N, Hammad I, Capuano S, Martin M, Schinazi R, Silvestri G, Kulpa D, Kumar P, Chomont N, Pazgier M, Smith A, Sodroski J, Evans D, Finzi A, Paiardini M. Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques. Journal Of Virology 2025, 99: e00062-25. PMID: 40192306, PMCID: PMC12090809, DOI: 10.1128/jvi.00062-25.Peer-Reviewed Original ResearchConceptsSHIV-infected rhesus macaquesShock-and-kill approachADCC-mediating antibodiesCD4-inducedHIV-1Rhesus macaquesDosing regimenSmall-molecule CD4-mimetic compoundsGp120 subunit of EnvLatent HIV-1 reservoirHIV-1 envelope glycoproteinAnti-HIV-1 antibodiesInfected cellsPlasma of treated animalsCD4-mimetic compoundsCure HIV-1HIV-1 reservoirUninfected rhesus macaquesPlasma viral loadBind to infected cellsHIV-1 EnvNon-neutralizing antibodiesCD4-bound conformationSerum half-livesViral rebound
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply